Axogen Stock Soars on FDA Approval for Nerve Repair Treatment
Axogen shares jumped 7% in premarket trading after FDA approved its Avance nerve repair treatment for adults and children, strengthening its market position.
/ 907 items
#Healthcare↓
Goldman Sachs Upgrades Taysha Gene Therapies on Rett Syndrome Potential
Goldman Sachs upgrades Taysha Gene Therapies to Buy with an $11 target, citing strong confidence in the company’s Rett syndrome program and REVEAL study expectations.
Stifel Bullish on Foghorn Therapeutics Stock
Stifel starts Foghorn Therapeutics coverage with Buy rating and $12 target. Lead drug FHD-909 partnership with Eli Lilly expected to launch in 2030 with strong sales potential.
Incannex IHL-42X Secures FDA Fast Track for OSA Treatment
Incannex's oral drug (IHL-42X) for serious sleep apnea (OSA) got FDA Fast Track status to speed up its development and potential approval.
Guggenheim Downgrades Black Diamond Therapeutics on Silevertinib Concerns
Guggenheim lowers Black Diamond Therapeutics to Neutral, citing toxicity and durability concerns in silevertinib’s Phase 2 trial and risks to key 2026 catalysts.
Protara Therapeutics Shares Climb on Strong Phase 2 Trial Results for TARA-002
Protara Therapeutics stock jumped after positive Phase 2 interim results showed strong response rates for TARA-002 in non-muscle invasive bladder cancer patients.